Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI7247 in Relapsed/Refractory Hematological Malignancies
NCT03106428Phase 1Completed
- Sponsor
- MedImmune
- Start
- Mar 2017
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of MEDI7247 in acute myeloid leukemia (AML), multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL) (3 cohorts), sponsored by MedImmune. Primary endpoints: Occurrence of adverse events, Occurrence of serious adverse events and 1 more. Started Mar 2017; status: completed.
02
Drugs
MEDI7247
03
Conditions
acute myeloid leukemia (AML)multiple myeloma (MM)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03106428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03106428.